Inotuzumab ozogamicin (INO) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody conjugated to calicheamicin, a potent cytotoxic agent. We performed a phase I/II study to determine the maximum-tolerated dose (MTD), safety, efficacy, and pharmacokinetics of INO plus rituximab (R-INO) for treatment of relapsed/refractory CD20 ϩ / CD22 ϩ B-cell non-Hodgkin lymphoma (NHL).
INTRODUCTION
Most non-Hodgkin lymphomas (NHLs) are of B-cell origin. 1 Because CD22, a B-cell antigen, is expressed in more than 90% of B-cell lymphoid malignancies, 2 is not expressed on lymphocyte precursor cells or memory B cells, and is internalized on antibody binding, 3 it is an attractive target for treatment of B-cell NHL. Inotuzumab ozogamicin (INO; CMC-544) was designed to take advantage of these properties, combining a humanized immunoglobulin G4 anti-CD22 antibody (G544) with the cytotoxic antibiotic calicheamicin. [4] [5] [6] [7] Internalization of CD22 allows for the release of calicheamicin to induce apoptosis. 3, 8, 9 A phase I monotherapy study 10 with relapsed/refractory CD22 ϩ NHL. Given these phase I results and data demonstrating synergy between INO and rituximab in animal models, 11, 12 this study evaluated preliminary safety and efficacy of the combination of rituximab and INO (R-INO) in patients with relapsed/refractory NHL.
PATIENTS AND METHODS

Patients
Patients with CD20 ϩ /CD22 ϩ B-cell NHL 13 and prior rituximab exposure were enrolled onto dose-escalation (DE) cohorts or were assigned to one of three groups at the MTD: relapsed follicular lymphoma (FL), relapsed diffuse large B-cell lymphoma (DLBCL), or refractory aggressive NHL (eligible subtypes: DLBCL, transformed FL, follicular grade 3b, or mantle cell; Fig 1) . Refractory was defined as disease progression less than 6 months from the start of the most recent rituximab-containing treatment. The relapsed groups included patients who had received two or fewer prior therapies and were not refractory to rituximab-containing therapy. The refractory group included patients who had received one or more prior therapies and had no response or were refractory to the most recent rituximab-containing treatment. Testing for CD22 was performed locally. See Appendix (online only) for more eligibility details.
The study was approved by each site's institutional review board and conducted in accordance with good clinical practice guidelines. Patients provided signed and dated informed consent before enrollment.
Study Design
This was a multicenter, open-label study. R-INO was administered once every 4 weeks: rituximab on day 1and INO on day 2 of each cycle. Up to eight cycles were planned. The study was performed in two parts: DE to define the MTD (part 1) and an expanded cohort to further evaluate efficacy and safety of the MTD (part 2).
In part 1, INO doses of 0.8 mg/m 2 , 1.3 mg/m 2 , and 1.8 mg/m 2 were selected. Rituximab was administered at a fixed dose of 375 mg/m 2 . Three to six patients with relapsed NHL were planned to enroll for each dose (Appendix). DE continued up to 1.8 mg/m 2 or until two or more of six patients experienced a dose-limiting toxicity (DLT; Appendix; Table 1 ). Patients with a DLT were to have subsequent doses reduced by one level; one dose reduction was allowed. In part 2, additional patients were enrolled to further evaluate safety and efficacy of the MTD, including follow-up for progression-free survival (PFS) and overall survival (OS).
Evaluations
All patients receiving one or more cycles of R-INO were evaluated for safety. Efficacy analyses were performed on an intent-to-treat basis for all patients enrolled to receive the MTD. Response to treatment was defined according to the version of the International Working Group (IWG) Response Criteria for NHL available at the time study recruitment began (May 2006) 14 ; PFS was measured from start of treatment until the first date of relapsed disease or progression, initiation of a new anticancer therapy, or death, censored at the last tumor evaluation date. OS was measured from the first dose until date of death, censored at the last date the patient was known to be alive.
Statistical Analysis and Pharmacokinetics/Pharmacodynamics
Details regarding statistical analysis are included in the Appendix. Table 2 and Figures 2A and 2B provide information about pharmacokinetic (PK) and pharmacodynamic parameters. (*) An additional patient was enrolled over the six planned patients because one patient was unevaluable for safety (increased aminotransferase levels at screening in violation of study eligibility criteria and confirmed alcohol abuse). ( †) All patients who received one or more doses of rituximab plus inotuzumab ozogamicin. One patient with DLBCL who was enrolled onto part 2 did not receive study treatment. ( ‡) All patients enrolled to receive MTD treatment (intent-to-treat): seven in part 1, 104 in part 2. One patient with DLBCL enrolled onto part 2 did not receive study treatment.
RESULTS
Patients
Of 119 enrolled patients, 118 received one or more cycles of R-INO ( Fig 1) . Characteristics of enrolled patients are summarized in Table 3 .
Summary of R-INO Treatment
For part 1, 15 patients received R-INO during DE. Five patients received INO 0.8 mg/m 2 , three received INO 1.3 mg/m 2 , and seven received INO 1.8 mg/m 2 in combination with rituximab at 375 mg/m 2 once every 4 weeks. An additional patient was enrolled because one patient was unevaluable for safety ( Fig 1) . Criteria for stopping DE were not met: no DLTs were observed at the 0.8 mg/m 2 or 1.3 mg/m 2 dose levels, and only one of seven patients had a DLT (delayed dosing was the result of low neutrophils and platelets) at the highest planned INO dose (1.8 mg/m 2 ). MTD for the regimen was declared to be 375 mg/m 2 rituximab day 1 and 1.8 mg/m 2 INO day 2 once every 4 weeks.
For part 2, 104 patients were enrolled with 103 dosed in the expanded MTD cohort. Collectively, 110 patients were treated at the declared MTD across study parts 1 and 2 (Fig 1) . Median number of cycles at the MTD was five (range, one to eight cycles) for FL, four (range, one to eight cycles) for DLBCL, and two (range, one to eight NOTE. Investigator-reported adverse events occurring in Ն 15% patients (MedDRA preferred term). Includes all patients who received one or more cycles of MTD treatment during the study (n ϭ 110): n ϭ 7 during part 1 (including five patients with FL and two patients with DLBCL), and n ϭ 103 during part 2. Toxicities were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, v3.0. MTD, rituximab 375 mg/m 2 day 1 and inotuzumab ozogamicin 1.8 mg/m 2 day 2 every 4 weeks declared after only one patient had a dose-limiting toxicity at the highest planned inotuzumab ozogamicin dose (1.8 mg/m 2 ). Dose-limiting toxicities were any of the following during the first cycle: febrile neutropenia, grade 4 neutropenia lasting Ն 7 days, grade 4 thrombocytopenia lasting Ն 3 days, grade 3 thrombocytopenia associated with hemorrhage requiring platelet transfusion, grade 3 to 4 nonhematologic toxicity (excluding nausea/vomiting not treated with optimal medical therapy and alopecia), and delayed recovery (grade 1/baseline) from a drug-related toxicity that prevented initiation of the next cycle by Ͼ 14 days. Abbreviations: AP, alkaline phosphatase; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; LDH, lactate dehydrogenase; MedDRA, Medical Dictionary for Regulatory Activities; MTD, maximum-tolerated dose; NHL, non-Hodgkin lymphoma.
‫ء‬
Infections and infestations presented by higher-level MedDRA system class (none Ն 15% by MedDRA preferred term). The most common infections were urinary tract infections, upper respiratory tract infections, and rhinitis.
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Efficacy
Objective response rate. At MTD treatment, objective response rate (ORR) was 87%, 74%, and 20% for patients with FL, DLBCL, and refractory disease, respectively (Figs 3A to 3C). Confirmed complete response (CR) and unconfirmed CR were achieved in 62% of patients with FL and 50% of patients with relapsed DLBCL. Within the refractory aggressive NHL group, responses were observed for each NHL subtype ( Fig 3C) . Median duration of response was 17.7 months for relapsed DLBCL, 6.1 months for refractory aggressive NHL and, at the time of this report, had not been reached for patients with FL (median follow-up, 40 months).
PFS and OS. One-and 2-year PFS rates were 87% and 68%, respectively, for FL (median PFS, not reached) and 55% and 42%, respectively, for relapsed DLBCL (median PFS, 17.1 months; Fig 3D) . For patients with refractory disease, median PFS was 1.9 months with a 2-year PFS rate of 10%. One and 2-year OS rates were 97% and 90%, respectively, for relapsed FL and 80% and 69%, respectively, for relapsed DL-BCL. In total, 36% of patients with refractory disease were alive at 2 years (median OS, 8.8 months). Median OS had not been reached for either the FL or relapsed DLBCL groups at the time of this report (median follow-up, 40 months for FL, with 82% of patients censored and 30 months for DLBCL with 69% of patients censored; Fig 3E) .
Efficacy and Prognostic Factors
Follicular Lymphoma International Prognostic Index (FLIPI) score 15 and tumor bulk appeared to affect CR and PFS rates in FL. Concentrations of inotuzumab ozogamicin, total calicheamicin (antibody conjugated and unconjugated forms), free (unconjugated) calicheamicin, and the parent G544 antibody were determined in serum by using a validated enzyme-linked immunosorbent assay as previously described. 10 Serum concentration-time profiles were constructed for each patient and analyzed by using a noncompartmental method (Jusko WJ: Guidelines for collection and analysis of pharmacokinetic data, in Evans WE, Schentag JJ, Jusko WJ, et al ͓eds͔:
Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring ͓ed 3͔. Vancouver, WA, Applied Therapeutics, 1992). Includes 2,336 observations from 110 patients for inotuzumab ozogamicin, 2,356 observations from 112 patients for total calicheamicin, 1,876 observations from 101 patients for unconjugated calicheamicin, and 2,413 observations from 117 patients for immunoglobulin G4 anti-CD22 antibody (G544) following administration of all doses. For inotuzumab ozogamicin, and to some extent for total calicheamicin, estimates of t 1/2 and CL were not obtainable because of the inability to characterize the terminal linear concentration phase. Pharmacokinetic profiles and parameters for unconjugated calicheamicin were not derived because most measures were below the limit of quantitation. Concentrations for G544 were qualitatively similar to those for inotuzumab ozogamicin and are not shown. Activity of R-INO in relapsed/refractory DLBCL appeared to be affected by International Prognostic Index (IPI) score, 16 tumor bulk, response to prior therapy, and prior time-to-tumor progression (Table 4) .
Safety
For all patients who received R-INO (n ϭ 118), the most common AEs included thrombocytopenia (56%), nausea (57%), fatigue (53%), increased AST (41%), neutropenia (33%), increased alkaline phosphatase (30%), and vomiting (28%).
At MTD treatment (n ϭ 110; Table 1 ), thrombocytopenia and neutropenia were the most frequent grade 3 to 4 events (9% of patients had grade 4 thrombocytopenia; 8% of patients had grade 4 neutropenia). Increases in AST, ALT, bilirubin, alkaline phosphatase, and lactate dehydrogenase were also observed, but grade 3 to 4 reports were rare (each Յ 4.5%). There were no grade 4 occurrences of increases in aminotransferase or bilirubin. Grade 3 increases in AST and ALT were generally reversible; in total, five (83%) of six patients with grade 3 AST or ALT had levels return to grade Յ 1 for continued dosing (without cycle delay, or within the 21-day delay period), and only one 
‫ء‬
Includes one patient who received 0.8 mg/m 2 inotuzumab ozogamicin and two patients who received 1.3 mg/m 2 inotuzumab ozogamicin during dose-escalation phase (part 1). †Includes four patients who received 0.8 mg/m 2 inotuzumab ozogamicin and one patient who received 1.3 mg/m 2 inotuzumab ozogamicin during dose-escalation phase (part 1).
‡Consists of patients with DLBCL (n ϭ 20), transformed FL (n ϭ 5), and mantle cell lymphoma (n ϭ 5). §Missing ECOG data (FL, n ϭ 1; DLBCL, n ϭ 3; refractory groups, n ϭ 1), FLIPI/IPI data (DLBCL, n ϭ 2; refractory groups, n ϭ 4), LDH data (DLBCL, n ϭ 1; refractory groups, n ϭ 1), and bone marrow involvement data (FL, n ϭ 2; DLBCL, n ϭ 1; refractory groups, n ϭ 1).
¶Includes nine patients with three prior therapies, seven patients with four prior therapies, and two patients with six prior therapies; one patient with Richter's transformation received nine prior therapies. Of the patients treated with R-INO, 30% experienced serious AEs. Serious AEs for more than one patient included pneumonia (n ϭ 5; 4%); sepsis (n ϭ 4; 3.4%); thrombocytopenia, vomiting, or nausea (n ϭ 3 [for each AE]; 2.5% each); and nodular regenerative hyperplasia, peripheral edema, duodenal ulcer, infection, chest pain, or dizziness (n ϭ 2 [for each AE]; 1.7% each). In addition to the two patients with nodular regenerative hyperplasia, there were three other serious hepatic events: grade 3 aminotransferase increase (reported as cytolytic hepatitis), hepatic fibrosis, and hepatic failure (fatal) in one patient each. For the two patients with nodular regenerative hyperplasia, one patient's condition (which resolved) was confirmed by liver biopsy approximately 1 year after five cycles of R-INO; the other patient (whose condition still had not resolved at last report) presented with ascites, increased bilirubin, and mild splenomegaly approximately 3 months after six cycles of R-INO. The patient with cytolytic hepatitis had increased liver function tests (AST/ALT) that resolved within 7 days. One patient had hepatic fibrosis that occurred 10 months after study treatment and was confounded by alcohol abuse. One patient with hepatic failure had previously been treated with with CHOP [cyclophosphamide, doxorubicin, vincristine, prednisone], then with R-DHAP [rituximab plus dexamethasone, cisplatin, cytarabine], and then was consolidated with BEAM [carmustine, etoposide, cytarabine, melphalan] and autologous stem-cell transplantation. The patient received five cycles of R-INO, had disease progression, and was then treated with R-CHOP [rituximab plus CHOP], which was complicated by febrile neutropenia, sepsis, and hepatic failure. The relationship between R-INO and this event is difficult to discern because the subsequent R-CHOP regimen could be a significant factor as well.
Forty patients (34%) have died. The most common reasons for death were disease progression (n ϭ 22), pneumonia (n ϭ 3), and multiorgan failure (n ϭ 3, including two associated with sepsis). Three deaths occurred at 30 days of treatment or before: two as a result of disease progression and one as a result of perforated bowel with bulky intestinal mass resulting in sepsis and death.
During MTD treatment, 47 patients (43%) had toxicities requiringdosedelays,and10patients(9%)requireddosereductions.Thrombocytopenia and neutropenia were the most common reasons for these dosing modifications. Fifty-four patients (49%) discontinued MTD treatment because of toxicities. Grade Ն 2 thrombocytopenia or hyperbilirubinemia lasting more than 3 weeks after the scheduled day of dosing were the most common reasons that patients discontinued MTD treatment. Twenty patients (18%) discontinued treatment because of thrombocytopenia: of these, 13 patients (65%) recovered to grade Յ 1 (approximately 2 to 10 months after last dose); five (25%) withlimitedfollow-uplaboratorydatadidnotrecoverbyapproximately2 months after last dose; and one (5%) did not recover by 8 months after the last dose, although new anticancer therapy was also initiated during this period (no data were available for one patient). Of note, 22% of patients treated at MTD had thrombocytopenia at baseline before dosing (study eligibility required platelets Ն 75,000/L). Nineteen patients (17%) discontinued treatment because of hyperbilirubinemia, and most (79%) had grade 1 to 2 increases. In total, 65% of all MTD discontinuations due to thrombocytopenia occurred within three or fewer cycles of R-INO, whereas 90% of all MTD discontinuations due to hyperbilirubinemia occurred after cycle 4 or greater.
Pharmacokinetics and Pharmacodynamics
Summaries of pharmacokinetic parameters are shown in 
DISCUSSION
R-INO presents a novel treatment for NHL with INO and rituximab targeting the CD22 and CD20 antigens, respectively. On the basis of cycle 1 DLTs, this combination of INO 1.8 mg/m 2 and a standard dose of rituximab 375 mg/m 2 (once every 4 weeks) was determined to be at or below the MTD. With repeated dosing, patients with relapsed DLBCL or FL were able to tolerate a median of four to five cycles. At this dose and schedule, many patients with prior chemotherapy treatment may not be able to tolerate more than six cycles without dose delays or reductions. For R-INO, 2-year PFS rates of 68% (median not reached) in patients with relapsed FL and 42% (median, 17.1 months) in patients with relapsed DLBCL were achieved compared with single-agent INO, which yielded a median PFS of 10.4 months and 1.6 months for the analogous NHL subtypes in a completed phase I study. 10 The different patient populations partly account for the increased efficacy observed for R-INO. Patients in the monotherapy trial (61% had four or more prior therapies and included those with refractory disease) more closely resemble the heavily pretreated refractory group in this study (63% with three or more prior therapies) who had an ORR of 20% and median PFS of 1.9 months. Still, nonclinical data with Ramos B-lymphoma xenograft models support at least additive effects between INO and rituximab, 11 and the increased activity seemingly conferred by the addition of rituximab to INO was expected, given that its addition has increased the efficacy of other chemotherapies. [17] [18] [19] [20] As with MTD treatment with single-agent INO, 10 the main grade 3 to 4 toxicities observed with MTD treatment with R-INO were thrombocytopenia and neutropenia. The frequency of these hematologic toxicities for R-INO was lower than that observed with INO monotherapy (31% and 22%, respectively, for R-INO; 63% and 35%, respectively, for monotherapy), 10 and likely related to differences in patient populations, with patients in the monotherapy study being more heavily pretreated (see Discussion, first paragraph) than those in the this study (79% with two or fewer prior therapies). Thrombocytopenia was the primary reason for discontinuation of treatment with R-INO.
Hepatotoxicity has also been observed with INO. In the monotherapy study, one patient developed veno-occlusive disease (VOD), although a medical history significant for VOD-like syndrome with prior therapy was noted. 10 No VOD occurred in this study, but other notable serious hepatotoxicity included two occurrences of nodular regenerative hyperplasia, one of hepatic fibrosis, and one of hepatic failure, although other factors including other chemotherapies or alcohol abuse may have contributed. Increased liver function tests and hyperbilirubinemia were also observed in this study but were primarily lower grade ( Table  1 ). Onset of hyperbilirubinemia was most likely to occur after multiple cycles of R-INO (90% of MTD discontinuations because of hyperbilirubinemia occurred after cycle four or greater). Thirteen patients (11%) had serious infections, with pneumonia being most common (n ϭ 5). Only one patient had febrile neutropenia.
Despite the targeted design of R-INO and studies showing that INO directlybindstoCD22receptorsandtargetsBcells(Figs2Aand2B),some toxicities indicate that nontarget effects still occur. Risk for some of these toxicities may be linked with increased cumulative INO exposure following multiple cycles resulting from decreased CD22 antigen sink. Increased exposure with repeated dosing may have contributed to discontinuation of treatment because of AEs following cycle 1. Dose reductions after cycle 1 may allow more cycles in some patients. Although preliminary analyses suggestexposure(AUC last )oftotalcalicheamicinwaspositivelycorrelated with an increase in AST in cycle 1, the effect was not evident at subsequent cycles. Further analyses may be helpful to better understand potential associations between exposure and nontarget effects.
The nonlinear PK of INO found in this study, marked by disproportionate increases in partial area under the curve and decreases in systemic clearance with dose and cycle, is characteristic of therapeutic antibodies that undergo target-mediated drug disposition. Internalization and disposition of the drug-target complex from the cell surface further contributes to the overall systemic clearance, with the effect of target-mediated drug disposition on the PK of an antibody typically more prominent at lower doses than higher doses because of target saturation in the latter case.
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In the context of current treatments, activity of R-INO is noteworthy. For relapsed/refractory FL, commonly used multiagent chemotherapies as well as the combination of rituximab and bendamustine yield high response rates (85% to 94%) and long PFS (median, 33 months) in patient populations inclusive of those not previously treated with rituximab. 17, 20, 21 Single-agent rituximab is expected to have ORR rates of approximately 50% in patients with relapsed/refractory FL. 22, 23 Thus, R-INO appears to be promising therapy for patients with relapsed FL,includingthosewithpriorrituximabexposure,potentiallybeingmore efficacious than single-agent rituximab and a particularly good option for those not suited for intensive multiagent therapies.
For more aggressive NHLs, salvage therapy with autologous stem-cell transplantation is generally regarded as the best option for those who are qualified. One-year PFS rates of approximately 38% to 42% and a 3-year PFS rate of 30% have been reported for patients with relapsed/refractory DLBCL who have had prior rituximab exposure. 24, 25 In these studies, most patients had only one prior therapy and were approximately age 55 years. Although the different patient populations make direct comparison difficult, R-INO efficacy in relapsed DLBCL appears notable, given the advanced age of patients with relapsed DLBCL in this trial (median age, 72 years).
R-INO treatment of patients with refractory aggressive NHL was challenging. Chemosensitivity of aggressive NHL appears to be a primary determinant of response to R-INO. Other baseline characteristics, including heavy pretreatment (Table 3) , could also be relevant. Still, within this refractory population, responses were observed for each NHL subtype: onepatientwithmantlecellNHLhadcompleteradiographicreductionof lesions, and three patients with DLBCL and two patients with transformed FL each had Ն 75% lesion reduction ( Fig 3C) .
In addition to prior rituximab exposure, other factors have been previously identified to adversely affect efficacy. 24, 26, 27 Response to prior therapy, time-to-progression with prior therapy, IPI score, and tumor bulkappeartoaffectR-INOoutcomesinpatientswithrelapsed/refractory DLBCL (Table 4 ). Complete responders with prior treatment had the highest response rates and longest PFS. For relapsed FL, high-risk FLIPI scores and tumor bulk appeared to have an adverse impact on CR rates and 1-year PFS rates, although response to prior therapy and prior timeto-tumor progression appeared less important (Table 4 ).
In conclusion, R-INO yielded high response rates and long PFS for relapsed FL and DLBCL. R-INO activity in the context of prior rituximab exposure is significant, given the current prevalence of first-line rituximab treatment. As in reports for other chemotherapies, possible adverse prognostic factors included high FLIPI/IPI scores, poor response or early relapse to prior treatment, and greater tumor bulk. Toxicity of R-INO is characterized primarily by manageable thrombocytopenia and neutropenia. Increases in liver function tests and hyperbilirubinemia (primarily grade 1 to 2 in this study) will continue to be evaluated in ongoing and future trials, along with PK studies to evaluate potential correlations between exposure and toxicity. R-INO may offer the reduction of certain toxicities such as febrile neutropenia compared with other multiagent chemotherapies. Results for relapsed/refractory DLBCL are promising, given that the patient population (risk factors include advanced age, heavy pretreatment, and poor response to prior therapy) represents a group with limited treatment options. Future studies comparing R-INO to other chemotherapies will help define the role for R-INO in treatment of CD22 ϩ malignancies.
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